JP2017531693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531693A5 JP2017531693A5 JP2017538177A JP2017538177A JP2017531693A5 JP 2017531693 A5 JP2017531693 A5 JP 2017531693A5 JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017531693 A5 JP2017531693 A5 JP 2017531693A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- population
- epicensus
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059506P | 2014-10-03 | 2014-10-03 | |
| US201462059497P | 2014-10-03 | 2014-10-03 | |
| US62/059,506 | 2014-10-03 | ||
| US62/059,497 | 2014-10-03 | ||
| PCT/US2015/054067 WO2016054654A1 (en) | 2014-10-03 | 2015-10-05 | Hiv vaccines comprising one or more population episensus antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170852A Division JP7212020B2 (ja) | 2014-10-03 | 2020-10-09 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017531693A JP2017531693A (ja) | 2017-10-26 |
| JP2017531693A5 true JP2017531693A5 (enExample) | 2018-11-15 |
Family
ID=55631703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538177A Pending JP2017531693A (ja) | 2014-10-03 | 2015-10-05 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
| JP2020170852A Active JP7212020B2 (ja) | 2014-10-03 | 2020-10-09 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
| JP2023003194A Active JP7441340B2 (ja) | 2014-10-03 | 2023-01-12 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170852A Active JP7212020B2 (ja) | 2014-10-03 | 2020-10-09 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
| JP2023003194A Active JP7441340B2 (ja) | 2014-10-03 | 2023-01-12 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10894078B2 (enExample) |
| EP (1) | EP3200878B1 (enExample) |
| JP (3) | JP2017531693A (enExample) |
| KR (1) | KR102633096B1 (enExample) |
| CN (1) | CN108064181A (enExample) |
| AU (2) | AU2015327797A1 (enExample) |
| CA (1) | CA2963573C (enExample) |
| EA (1) | EA201790680A1 (enExample) |
| HK (1) | HK1254806A1 (enExample) |
| IL (1) | IL251469B2 (enExample) |
| MA (1) | MA40783A (enExample) |
| MX (3) | MX391149B (enExample) |
| SG (1) | SG11201702729YA (enExample) |
| UA (1) | UA126890C2 (enExample) |
| WO (1) | WO2016054654A1 (enExample) |
| ZA (1) | ZA202206809B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| CA3028982A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| US20210317192A9 (en) * | 2019-05-29 | 2021-10-14 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| BR112022003474A2 (pt) | 2019-08-29 | 2022-05-24 | Triad Nat Security Llc | Vacinas do vírus da hepatite b |
| CN116847882A (zh) * | 2021-01-14 | 2023-10-03 | 吉利德科学公司 | Hiv疫苗及其使用方法 |
| CA3202466A1 (en) * | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
| CN117836311A (zh) * | 2021-08-31 | 2024-04-05 | 维尔生物科技公司 | 用于产生cmv载体的方法 |
| US20240384296A1 (en) | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| TW202436326A (zh) * | 2023-02-13 | 2024-09-16 | 長怡 王 | 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者 |
| CN116524994B (zh) * | 2023-02-20 | 2026-01-30 | 中国科学院天津工业生物技术研究所 | 一种基于贪婪算法的菌株构建排程设计方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| JP4601956B2 (ja) | 2001-09-20 | 2010-12-22 | グラクソ グループ リミテッド | Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン |
| AUPR842501A0 (en) * | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| WO2005012502A2 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| AU2011203095A1 (en) | 2003-09-17 | 2011-07-21 | Duke University | Consensus/Ancestral Immunogens |
| CA2539325C (en) * | 2003-09-17 | 2016-03-22 | Duke University | Consensus/ancestral immunogens |
| WO2005035779A2 (en) | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc | Method |
| AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
| US8119140B2 (en) | 2005-08-23 | 2012-02-21 | Los Alamos Security, LLC | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins |
| KR102511874B1 (ko) | 2006-07-28 | 2023-03-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
| WO2008118497A1 (en) * | 2007-03-27 | 2008-10-02 | President And Fellows Of Harvard College | Rhadinovirus vectors for expressing of immunodeficiency virus antigen |
| US20100183651A1 (en) | 2007-03-30 | 2010-07-22 | Finnefrock Adam C | Broadly Representative Antigen Sequences and Method for Selection |
| PL2358757T3 (pl) | 2008-11-18 | 2019-02-28 | Beth Israel Deaconess Medical Center | Szczepionki antywirusowe o ulepszonej immunogenności komórkowej |
| JP2013507107A (ja) * | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成 |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| US8557787B2 (en) | 2011-05-13 | 2013-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| EP2820035B1 (en) | 2012-03-02 | 2019-01-09 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions |
| WO2014107744A1 (en) * | 2013-01-07 | 2014-07-10 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| JP2017507672A (ja) | 2014-02-28 | 2017-03-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法 |
| NZ728208A (en) | 2014-07-16 | 2018-07-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
| MA40765B1 (fr) | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| PL3390430T3 (pl) | 2015-12-15 | 2020-03-31 | Janssen Vaccines & Prevention B.V. | Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania |
-
2015
- 2015-10-04 MA MA040783A patent/MA40783A/fr unknown
- 2015-10-05 UA UAA201704021A patent/UA126890C2/uk unknown
- 2015-10-05 MX MX2017004275A patent/MX391149B/es unknown
- 2015-10-05 JP JP2017538177A patent/JP2017531693A/ja active Pending
- 2015-10-05 US US15/516,491 patent/US10894078B2/en active Active
- 2015-10-05 WO PCT/US2015/054067 patent/WO2016054654A1/en not_active Ceased
- 2015-10-05 HK HK18113892.2A patent/HK1254806A1/zh unknown
- 2015-10-05 KR KR1020177012171A patent/KR102633096B1/ko active Active
- 2015-10-05 CN CN201580063643.3A patent/CN108064181A/zh active Pending
- 2015-10-05 AU AU2015327797A patent/AU2015327797A1/en not_active Abandoned
- 2015-10-05 EA EA201790680A patent/EA201790680A1/ru unknown
- 2015-10-05 SG SG11201702729YA patent/SG11201702729YA/en unknown
- 2015-10-05 CA CA2963573A patent/CA2963573C/en active Active
- 2015-10-05 EP EP15847978.2A patent/EP3200878B1/en active Active
- 2015-10-05 IL IL251469A patent/IL251469B2/en unknown
-
2017
- 2017-03-31 MX MX2022003664A patent/MX2022003664A/es unknown
- 2017-03-31 MX MX2022003663A patent/MX2022003663A/es unknown
-
2020
- 2020-08-31 US US17/008,335 patent/US11554168B2/en active Active
- 2020-08-31 US US17/008,289 patent/US11628215B2/en active Active
- 2020-10-09 JP JP2020170852A patent/JP7212020B2/ja active Active
-
2021
- 2021-08-19 AU AU2021218141A patent/AU2021218141B2/en active Active
-
2022
- 2022-06-20 ZA ZA2022/06809A patent/ZA202206809B/en unknown
-
2023
- 2023-01-12 JP JP2023003194A patent/JP7441340B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2949851C (en) | Htert sequences and methods for using the same | |
| Doria-Rose et al. | Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge | |
| Lu | Heterologous prime–boost vaccination | |
| McShane et al. | Prime-boost immunisation strategies for tuberculosis | |
| Hanke | Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines | |
| Ross et al. | Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference | |
| Earl et al. | Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate | |
| Paris et al. | Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1 | |
| Karpenko et al. | Novel approaches in polyepitope T-cell vaccine development against HIV-1 | |
| Knudsen et al. | Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen | |
| Latanova et al. | Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity | |
| Larijani et al. | HIV-1 p24-nef DNA vaccine plus protein boost expands T-cell responses in BALB/c | |
| Ajbani et al. | Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and polRT genes | |
| Sundbäck et al. | Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles | |
| Anderson et al. | Overcoming original (antigenic) sin | |
| Shephard et al. | A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice | |
| van Harmelen et al. | Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa | |
| Clutton et al. | Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines | |
| Dereuddre-Bosquet et al. | HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations | |
| Klein | Prospects and challenges for prophylactic and therapeutic HIV vaccines | |
| Mayr et al. | Antibodies targeting the envelope of HIV‐1 | |
| Stenler et al. | Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses | |
| Kumar et al. | Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India | |
| Choi et al. | Enhancement of DNA vaccine-induced immune responses by influenza virus NP gene | |
| US9566329B2 (en) | Live, attenuated rubella vector to express vaccine antigens |